.Beta.-Hydroxyisovaleric Acid

.Beta.-Hydroxyisovaleric Acid

SCHEMBL5159905

CC(C)(O)CC(=O)[O-].CC(C)(O)CC(=O)[O-].[Mg+2]

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ATP4AATP4BGABBR1GABBR2HMGCR

The experimentally established mechanism targets of .Beta.-Hydroxyisovaleric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGCR known ✓ P04035 1/20 0.39
CA4 P22748 3/20 0.48
CHRM1 P11229 1/20 0.39
TBXA2R P21731 1/20 0.39
ADRA1A P35348 1/20 0.39
PIK3CD O00329 1/20 0.38
ALDH1A1 P00352 2/20 0.35
FFAR3 O14843 2/20 0.35
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
TSHR P16473 2/20 0.33
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
CA2 P00918 1/20 0.32
CASP1 P29466 1/20 0.32
CA1 P00915 2/20 0.32
TET2 Q6N021 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
.Beta.-Hydroxyisovaleric Acid SCHEMBL1409113 0.94
.Beta.-Hydroxyisovaleric Acid SCHEMBL10277344 0.94 CA4 (0.48) CA4HMGCRCHRM1TBXA2RADRA1A
.Beta.-Hydroxyisovaleric Acid SCHEMBL10276849 0.94
.Beta.-Hydroxyisovaleric Acid SCHEMBL723160 0.94 CA4 (0.48) CA4HMGCRCHRM1TBXA2RADRA1A
.Beta.-Hydroxyisovaleric Acid SCHEMBL2127978 0.92 CA4 (0.46) CA4HMGCRCHRM1TBXA2RADRA1A
.Beta.-Hydroxyisovaleric Acid SCHEMBL5162721 0.92 CA4 (0.46) CA4HMGCRCHRM1TBXA2RADRA1A
.Beta.-Hydroxyisovaleric Acid SCHEMBL32674118 0.85 HMGCR (0.50) CA4HMGCRCHRM1TBXA2RADRA1A
.Beta.-Hydroxyisovaleric Acid SCHEMBL5578340 0.85 PIK3CD (0.42) CA4HMGCRCHRM1TBXA2RADRA1A
SCHEMBL10887232 0.79 CA4 (0.43) CA4HMGCRCHRM1TBXA2RADRA1A
SCHEMBL38654757 0.74 CA4 (0.40) CA4HMGCRCHRM1TBXA2RADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11248146-B2 Polyvinyl acetal resin composition, film for laminated glass, and laminated glass SKC CO., LTD. (KR) 2022-02-15 US claimed
CN-113166475-B Polyvinyl acetal resin composition, film for bonded glass, and bonded glass SKC株式会社 2022-01-04 CN claimed
US-20210395574-A1 POLYVINYL ACETAL RESIN COMPOSITION, FILM FOR LAMINATED GLASS, AND LAMINATED GLASS SKC CO., LTD. (KR) 2021-12-23 US claimed
CN-113166475-A Polyvinyl acetal resin composition, film for bonded glass, and bonded glass SKC株式会社 2021-07-23 CN claimed
CN-111903871-A Feed additive, low-protein feed and preparation method and application thereof 中国科学院亚热带农业生态研究所 2020-11-10 CN claimed
WO-2020122355-A1 POLYVINYL ACETAL RESIN COMPOSITION, FILM FOR LAMINATED GLASS, AND LAMINATED GLASS 에스케이씨 주식회사 2020-06-18 WO claimed
WO-2016044272-A1 METHODS OF PRESERVING MUSCLE STRENGTH DURING A PERIOD OF MUSCLE DISUSE BY ADMINISTERING BETA-HYDROXY-BETA-METHYLBUTYRATE AND GREEN TEA EXTRACT ABBOTT LABORATORIES (US) 2016-03-24 WO claimed
US-8785496-B2 Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting ABBOTT LABORATORIES (US) 2014-07-22 US claimed
US-8785495-B2 Compositions including beta-hydroxy-beta-methylbutyrate ABBOTT LABORATORIES (US) 2014-07-22 US claimed
US-8778993-B2 Method of using β-hydroxy-β-methylbutyrate for the treatment of disease conditions ABBOTT LABORATORIES (US) 2014-07-15 US claimed
US-20120196829-A1 METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR THE PREVENTION AND TREATMENT OF DISEASE CONDITIONS ABBOTT LABORATORIES (US) 2012-08-02 US claimed
US-20120189717-A1 METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE AND FATTY ACIDS FOR TREATING DISEASE-ASSOCIATED WASTING ABBOTT LABORATORIES (US) 2012-07-26 US claimed
US-20120189714-A1 COMPOSITIONS INCLUDING BETA-HYDROXY-BETA-METHYLBUTYRATE ABBOTT LABORATORIES (US) 2012-07-26 US claimed
US-20120189716-A1 METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR TREATING DISEASE-ASSOCIATED WASTING ABBOTT LABORATORIES (US) 2012-07-26 US claimed
US-20120177752-A1 NUTRITIONAL COMPOSITIONS INCLUDING BETA-HYDROXY-BETA-METHYLBUTYRATE ABBOTT LABORATORIES (US) 2012-07-12 US claimed
EP-1750527-A1 COMPOSITIONS AND METHOD FOR ENHANCING THE BIOAVAILABILITY OF CALCIUM AND MAGNESIUM IN DIETARY SUPPLEMENTS AND FOOD ADDITIVES Wiley Organics, Inc. (US) 2007-02-14 EP claimed
WO-2005096846-A1 COMPOSITION AND METHOD FOR ENHANCING THE BIOAVAILABILITY OF CALCIUM AND MAGNESIUM IN DIETARY SUPPLEMENTS AND FOOD ADDITIVES WILEY ORGANICS, INC. (US) 2005-10-20 WO claimed
US-20040220266-A1 Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives WILEY ORGANICS, INC. 2004-11-04 US claimed
US-20040106678-A1 Compositions for the parenteral administration of calcium and magnesium DOBBINS THOMAS A 2004-06-03 US claimed
US-20040048925-A1 Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives WILEY ORGANICS, INC. 2004-03-11 US claimed